This article is more than 5 years old. Information may no longer be current.

Most Ahmed valve patients need additional IOP control by 4 years postop

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The Ahmed glaucoma valve can be safely used in eyes with uveitic glaucoma, although most patients will eventually require additional use of glaucoma medications to control IOP, according to a recent study.

Thekla G. Papadakia, MD, of Harvard Medical School, and colleagues reviewed records for 60 eyes of 60 patients who received the Ahmed valve for uveitic glaucoma.

At 1 year follow-up, 77% of patients experienced a 25% reduction in IOP to 21 mm Hg or lower, which was the study's definition of success, and 57% of these patients achieved success without serious complications, according to the study.

At 4 years, 50% of patients had achieved success, 39% of whom did so without serious complications. Also at 4 years, 74% of patients required glaucoma medications to control IOP, the authors reported.

The study is published in the July issue of American Journal of Ophthalmology.